Vascular endothelial growth factor genetic polymorphisms and susceptibility to age-related macular degeneration in Tunisian population

Table 2 Distribution of genotype and allele frequencies in patients and in controls; in subgroup and in response to anti-VEGF

SNPs		Patients n = 145	Controls n = 207	G1 n = 117	G2 n = 28	GR n = 52	PR n = 16
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
(−2578)	CC	19 (13.10)	38 (18.35)	16 (13.67)	3 (10.71)	4 (7.7)	4 (25)
	CA	67 (46.21)	88 (42.51)	57 (48.71)	10 (35.71)	24 (46.1)	9 (56.2)
	AA	59 (40.69)	81 (39.13)	44 (37.60)	15 (53.57)	24 (46.1)***	3 (18.8)
	C	0.362	0.397	0.380	0.286	0.308	0.531
	A	0.638	0.603	0.620	0.714	0.692	0.468
(+405)	GG	55 (37.93)*	97 (46,7)	46 (39.31)	9 (32.14)	15 (28.9)	7 (43.8)
	GC	51 (35.17)	92 (44.4)	42 (35.89)	9 (32.14)	21 (40.4)	6 (37.5)
	CC	39 (26.90)	18 (8.9)	29 (24.78)	10 (35.71)	16 (30.7)	3 (18.8)
	G	0.555*	0.688	0.573	0.482	0.490	0.625
	C	0.445	0.311	0.427	0.518	0.510	0.375
(+936)	CC	101 (69.65)	168 (81.1)	83 (70.94)	18 (64.28)	41 (78.8)	12 (75)
	CT	38 (26.21)	38 (18.3)	30 (25.64)	8 (28.57)	11 (21.1)	2 (12.5)
	TT	6 (4.14)**	1 (0.6)	6 (3.41)	2 (7.14)	0	2 (12.5)****
	C	0.828	0.903	0.838	0.786	0.894	0.810
	T	0.172**	0.097	0.179	0.214	0.106	0.190

*Homozygous GG genotype and G allele were significantly higher in AMD patients than in controls [(OR: 3.86, 95%CI [2.03 - 7.42], p = 5 × 10⁻⁶ and OR: 1.79, 95%CI [1.3 - 2.48], p = 2 × 10⁻⁴ respectively)].
**Homozygous TT genotype and T allele were significantly higher in AMD patients than in controls [(OR: 8.89, 95%CI [1. 05–198.1], p = 0.021 and OR: 1.95, 95%CI [1. 22–3.12], p = 0.003 respectively)].
***Homozygous AA (−2578) genotype was statistically associated with good response [(OR: 0.27, 95%CI [0.07- 1.06], p = 0.042)].
****Homozygous TT (+936) genotype was statistically associated with poor response [(OR: 1.61, 95%CI [0.31-8.28], p = 0.014].

ISSN: 2050-7771